Medicare And Lecanemab: House Republicans Lack ‘Proactive’ Plan For Ensuring Coverage

With a slim House majority, will Republicans wade into Medicare coverage policy for a promising Alzheimer’s drug and the new Medicare price negotiation program? Democratic Senate could offer ‘counter oversight’ hearings.

Looking Ahead To The Next Two Years In Congress • Source: Shutterstock

Congressional Republicans may need to “scramble” to help ensure meaningful Medicare coverage for Eisai Co., Ltd./Biogen, Inc.’s lecanemab if it is approved by the US Food and Drug Administration for Alzheimer's disease next year, according to health policy expert Jennifer Young.

Young who is a partner at the health care policy consultancy Tarplin, Downs and Young, discussed House Republican’s health care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Elections

More from Legislation